Are we facing a cure in lung cancer?-KEYNOTE-001 insights

Affiliations

Editorial

Aharon Y Cohen et al. Ann Transl Med. 2019 Sep.

. 2019 Sep;7(Suppl 6):S215.

doi: 10.21037/atm.2019.08.87.

¹ Oncology Division, The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001.
Akingbemi W, Garon E. Akingbemi W, et al. Ann Transl Med. 2020 Jun;8(11):728. doi: 10.21037/atm-2020-95. Ann Transl Med. 2020. PMID: 32617347 Free PMC article. No abstract available.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Garon EB, et al. J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2. J Clin Oncol. 2019. PMID: 31154919 Free PMC article. Clinical Trial.

1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed
1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-30. 10.1016/S0140-6736(18)32409-7 - DOI - PubMed
1. Diker O. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med 2018;379:e18. 10.1056/NEJMc1808567 - DOI - PubMed
1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed